Condition: Ventricular Tachycardia · Ischemic Heart Disease · Sustained VT · Sponsor: Pasquale Santangeli
ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.
This description comes directly from the study's public registry record.
Pasquale Santangeli, MD, PhD · 216-445-1940 · santanp3@ccf.org
Yuki Kuramochi, BSN, RN · 216-445-4063 · kuramoy@ccf.org
Always discuss trial participation with your own doctor first.
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06891456